Autopsy report · NCT02306876
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males
Cause of deathFunding or business, also safety
“Study recruitment was terminated on 14 June 2016 due to a Pfizer business decision. This study was not terminated for reasons of safety.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 5 months before it stopped.
- 77 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Healthy
- Interventions
- PF-06412562 3mg BID; PF-06412562 15mg BID; Placebo
- Participants
- 77
- Sites
- 3
- Countries
- United States
Trials that died the same way
- Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
“The study was terminated due to recruitment challenges” - Early Versus Late Amniotomy Following EAB Cervical Ripening
“Study was terminated due to difficulties in recruitment” - Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery
“The study was terminated due to a considerably lower recruitment rate than anticipated” - Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks
“Study terminated due to inadequate recruitment” - A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee System
“Study was terminated early due to prolonged recruitment period.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.